Inappropriate Antibiotic Prescribing Common for Women With UTIs
Many women receive prescriptions for inappropriate agents or durations; rural women more likely to receive Rx with inappropriately long duration
Urinary Tract Discomfort
MPR Weekly Dose Podcast Episode 68
This week we cover a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.
UTI Recurrence in Pediatric Patients: Antibiotic Treatment Duration Examined
Several factors were associated with an increased risk of UTI recurrence. These included antibiotic exposure prior to treatment, pyelonephritis on diagnosis date, having a follow-up visit during antibiotic treatment, receiving parenteral antibiotics.
Novel Antibiotic Sulopenem Misses Primary End Point in cIAI Trial
Results showed that sulopenem failed to demonstrate non-inferiority to ertapenem (difference of 4.7%; 95% CI: -10.3, 1.0); 85.5% of patients in the sulopenem arm had a clinical response vs 90.2% of the ertapenem group.
FDA Panel Votes on Novel Antibiotic for Complicated UTI
The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.
USPSTF Urges Asymptomatic Bacteriuria Screening in Pregnancy
No net benefit seen for screening, treatment of asymptomatic bacteriuria for nonpregnant adults
SGLT-2 Inhibitor Use Not Linked to Increased Risk for UTI Events
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
Facility Inspections, Manufacturing Deficiencies Hinder Approval of Contepo, According to FDA’s CRL
The FDA has issued a Complete Response Letter to Nabriva Therapeutics regarding the New Drug Application for Contepo (fosfomycin).
USPSTF Urges Asymptomatic Bacteriuria Screen in Pregnancy
The USPSTF recommends screening pregnant women for asymptomatic bacteriuria (ASB) but not nonpregnant women or men.
Nondihydropyridine CCBs May Be an Effective Treatment Option for Proteinuria in Certain Patients
Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease
